Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer [Corrigendum]
Chang J, Hong L, Liu Y. Cancer Manag Res. 2020;12:2641–2651. The authors have advised that there is an error in Figure 2E on page 2646. The authors apologize for this error. Read the original article
Main Authors: | Chang J, Hong L, Liu Y, Pan Y, Yang H, Ye W, Xu K, Li Z, Zhang S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-05-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/corrigendum-targeting-pik3cg-in-combination-with-paclitaxel-as-a-poten-peer-reviewed-article-CMAR |
Similar Items
-
Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer
by: Chang J, et al.
Published: (2020-04-01) -
Claudin 1 in Breast Cancer: New Insights
by: Bowen Zhou, et al.
Published: (2015-11-01) -
In Vivo Evaluation of Dual-Targeted Nanoparticles Encapsulating Paclitaxel and Everolimus
by: Loujin Houdaihed, et al.
Published: (2019-05-01) -
The Expression and Prognostic Significance of Claudin-8 and Androgen Receptor in Breast Cancer
by: Zhang Y, et al.
Published: (2020-04-01) -
Les claudines dans le cancer colorectal : ciblage thérapeutique de la claudine-1
by: Cherradi, Sara
Published: (2018)